A
Anebulo Pharmaceuticals, Inc. (ANEB)
PNK – Real Time Price. Currency in USD
0.52
+0.06 (13.04%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
0.52
+0.06 (13.04%)
At close: May 12, 2026, 4:00 PM EDT
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
| Name | Position |
|---|---|
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
| Mr. Daniel V. George | Acting CFO & Secretary |
| Mr. Richard Anthony Cunningham | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-02 | 15-12G | form15-12g.htm |
| 2026-02-17 | 25 | form25.htm |
| 2026-02-12 | 10-Q | form10-q.htm |
| 2026-02-06 | 8-K | form8-k.htm |
| 2026-01-29 | SC TO-I/A | formsctoia.htm |
| 2026-01-27 | SC TO-I/A | formsctoia.htm |
| 2026-01-08 | SC TO-I/A | formsc-toia.htm |
| 2025-12-22 | SC TO-I | formsc-toi.htm |
| 2025-12-22 | 8-K | form8-k.htm |
| 2025-11-13 | 10-Q | form10-q.htm |